PT - JOURNAL ARTICLE AU - Kristo Marvyin AU - Eirik Brekka Tjønnfjord AU - Unni Mathilde Breland AU - Geir Erland Tjønnfjord TI - Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment AID - 10.1136/bcr-2020-235816 DP - 2020 Sep 01 TA - BMJ Case Reports PG - e235816 VI - 13 IP - 9 4099 - http://casereports.bmj.com/content/13/9/e235816.short 4100 - http://casereports.bmj.com/content/13/9/e235816.full SO - BMJ Case Reports2020 Sep 01; 13 AB - Chronic lymphatic leukaemia (CLL) is the most common leukaemia in the Western world. Ibrutinib, a tyrosine kinase inhibitor, is the treatment of choice on relapse or p53-dysfunction. Richter’s transformation to diffuse large B cell lymphoma is most often seen. However, transformation to other aggressive lymphomas as plasmablastic lymphoma (PBL) does occur. PBL is an extremely aggressive lymphoma and is usually treated using a CHOP-like regimen (cyclophosphamide, doxorubicin, vincristine and prednisone/dexamethasone), but with poor outcome. The only curative treatment is allogeneic stem cell transplant (ASCT).We report on a case of CLL treated with ibrutinib that underwent transformation to PBL. Due to high expression of CD138, we added daratumumab to the chemotherapy with a good, but transitory response. The case did not make it to an ASCT. Targeting CD138 by daratumumab may be added to chemoimmune therapy for PBL.